. 2022 Apr 26;29(7):R85–R103. doi: 10.1530/ERC-21-0368
This work is licensed under a Table 2.
Registered (clinicaltrials.gov) clinical trials for the treatment of advanced and /or metastatic MTC.
| Clinical trial | ID | Molecule tested | Status of the study | Type of the study (phase) |
|---|---|---|---|---|
| MKIs | ||||
| Phase 1 and 2 | ||||
| - A Study of LOXO-292 in Participants With Advanced Solid Tumours, RET Fusion-Positive Solid Tumours and MTC | NCT03157128 | Selpercatinib (LOXO-292) | Recruiting | 1 and 2 |
| - Study of TPX-0046, a RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumours Harbouring RET Fusions or Mutations | NCT03647657 | TPX-0046 (third generation, highly selective TKI) | Recruiting | 1 and 2 |
| - A Study of HA121-28 Tablets in Patients With MTC | NCT04787328 | HA121-28 | Recruiting | 2 |
| - A Study Using Regorafenib as Second or Third-Line Therapy in Metastatic MTC | NCT02657551 | Regorafenib | Recruiting | 2 |
| - A Study Using Regorafenib as Second or Third-Line Therapy in Metastatic MTC | NCT02657551 | Regorafenib | Recruiting | 2 |
| - Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | NCT04759911 | Selpercatinib (LOXO-292) | Recruiting | 2 |
| - Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced or Recurrent MTC | NCT00390325 | Sorafenib tosylate | Active recruitment completed | 2 |
| - Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | NCT00381641 | Sunitinib malate | Active not recruited yet | 2 |
| - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumours Including RET Fusion-positive Solid Tumours, MTC and Other Tumours With RET Activation | NCT04280081 | Selpercatinib | Active not recruited yet | 2 |
| - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumour, or Other Rare Tumours | NCT02867592 | Cabozantinib-S-malate | Active not recruited yet | 2 |
| - Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | NCT00625846 | Pazopanib hydrochloride | Completed (2020) results pending | 2 |
| - Safety, Efficacy and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumours | NCT03780517 | BOS172738 (selective RET inhibitor) | 2 | |
| - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumour, or Other Rare Tumours | NCT02867592 | Cabozantinib-S-malate | Active not recruited yet | 2 |
| Phase 3 and 4 | ||||
| - A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant MTC | NCT04211337 | Selpercatinib, cabozantinib, vandetanib | Recruiting | 3 |
| - A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic MTC | NCT01896479 | Cabozantinib (XL184) 140 mg vs cabozantinib (XL184) 60 mg vs placebo | Active not recruited yet | 4 |
| - A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated MTC | NCT04760288 | Pralsetinib, cabozantinib, vandetanib | Active, not yet recruiting | 3 |
| - To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced MTC | NCT01496313 | Vandetanib 150 vs 300 mg | Active not recruited yet | 4 |
| - An Efficacy Study Comparing ZD6474 to Placebo in MTC | NCT00410761 | ZD6474 (vandetanib) | Active not recruited yet | 3 |
| - A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic MTC | NCT01896479 | Cabozantinib 60 vs 140mg | Active not recruited yet | 4 |
| ICIs (all phase 1 and 2) | ||||
| - A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma – The DUTHY Trial | NCT03753919 | Durvalumab | Recruiting | 2 |
| - A Phase 2 Study of Nivolumab Plus | NCT03246958 | Nivolumab+ipilimumab | Active not recruiting | 2 |
| - Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer | ||||
| - Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumours in Patients With HIV Infection | NCT04514484 | Nivolumab | Recruiting | 1 |
| - Phase II Trial of Pembrolizumab in Recurrent or Metastatic MTC | NCT03072160 | Pembrolizumab | Completed (results submitted) | 2 |
| - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | NCT03012620 | Pembrolizumab | Recruiting | 2 |
| PRRT (all phase 1 and 2) | ||||
| - Indium In 111 pentetreotid in treating patients with refractory cancer | NCT00002947 | 111In pentetreotid | Terminated | 1 |
| - 177Lu-PP-F11N in Combination With Sacubitril for Receptor-Targeted Therapy and Imaging of Metastatic Thyroid Cancer | NCT03647657 | 177Lu-PP-F11N | Recruiting | 1 |
| - 177Lu-PP-F11N for Receptor-Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed) | NCT02088645 | 177Lu-PP-F11N | Recruiting | 1 |
| - Radioactive Drug (177Lu-DOTATE) for the Treatment of Locally Advanced metastatic or Unresectable Rare Endocrine Cancers | NCT04106843 | 177Lu Dotatate | Recruiting | 2 |
| Others | ||||
| - GFRα4 CAR T Cells in MTC Patients | NCT04877613 | Single dose of CART-GFRa4 cells vs fludarabine vs cyclophosphamide | Recruiting | 1 |
| - Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | NCT04522570 | Laser ablation, cryoablation, radiofrequency ablation | Recruiting | n/a |
| - QUILT-3.006 for Recurrent MTC (vaccine) | NCT01856920 | GI-6207 (recombinant Saccharomyces cerevisiae-CEA (610D)) | Active not recruited yet | 2 |
Inhibitors, 177Lu-PP-F11N, 177Lutetium-labelled minigastrin analogue; ICI, immune-check point inhibitors; 111In, 111Indium; MKI, multikinase inhibitors; MTC, medullary thyroid cancer; PRRT, peptide receptor radionuclide therapy.